Insider · CIK 0001443841
Joseph Ciaffoni
Files at INDV (Indivior Pharmaceuticals, Inc.). First filing -, latest -.
Joseph Ciaffoni files SEC Form 4 as CEO and director at INDV (Indivior Pharmaceuticals, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Joseph Ciaffoni has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 22, 2026 | INDV Indivior Pharmaceuticals, Inc. | MOption exercise Common Stock | +1,266,903 | - | - | 1,402,879 | Jun 23, 2026 |
| Jun 22, 2026 | INDV Indivior Pharmaceuticals, Inc. | FTax withholding Common Stock | -612,549 | $38.32 | $23M | 790,330 | Jun 23, 2026 |
| Jun 22, 2026 | INDV Indivior Pharmaceuticals, Inc. | MOption exercise Performance Stock Unitsderivative | -1,266,903 | - | - | 0 | Jun 23, 2026 |
| Feb 10, 2026 | INDV Indivior Pharmaceuticals, Inc. | AGrant or award Common Stock | +79,976 | $0.00 | $0 | 135,976 | Feb 12, 2026 |
Questions about Joseph Ciaffoni
Answered from the filings on this page, as of the latest one.
Is Joseph Ciaffoni buying or selling?
Joseph Ciaffoni has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Joseph Ciaffoni's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Joseph Ciaffoni has 0.
Where does Joseph Ciaffoni file Form 4?
Joseph Ciaffoni has filed Form 4 at INDV (Indivior Pharmaceuticals, Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.